vs

Side-by-side financial comparison of First Foundation Inc. (FFWM) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $35.5M, roughly 1.4× RECURSION PHARMACEUTICALS, INC.). First Foundation Inc. runs the higher net margin — -97.9% vs -304.2%, a 206.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 421.7%). First Foundation Inc. produced more free cash flow last quarter ($-35.2M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -2.7%).

John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FFWM vs RXRX — Head-to-Head

Bigger by revenue
FFWM
FFWM
1.4× larger
FFWM
$48.4M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+260.1% gap
RXRX
681.7%
421.7%
FFWM
Higher net margin
FFWM
FFWM
206.4% more per $
FFWM
-97.9%
-304.2%
RXRX
More free cash flow
FFWM
FFWM
$12.1M more FCF
FFWM
$-35.2M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-2.7%
FFWM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FFWM
FFWM
RXRX
RXRX
Revenue
$48.4M
$35.5M
Net Profit
$-8.0M
$-108.1M
Gross Margin
59.8%
Operating Margin
-97.5%
-304.8%
Net Margin
-97.9%
-304.2%
Revenue YoY
421.7%
681.7%
Net Profit YoY
43.0%
39.6%
EPS (diluted)
$-0.09
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FFWM
FFWM
RXRX
RXRX
Q4 25
$48.4M
$35.5M
Q3 25
$63.6M
$5.2M
Q2 25
$51.4M
$19.2M
Q1 25
$71.4M
$14.7M
Q4 24
$9.3M
$4.5M
Q3 24
$9.2M
$26.1M
Q2 24
$57.5M
$14.4M
Q1 24
$51.1M
$13.8M
Net Profit
FFWM
FFWM
RXRX
RXRX
Q4 25
$-8.0M
$-108.1M
Q3 25
$-146.3M
$-162.3M
Q2 25
$-7.7M
$-171.9M
Q1 25
$6.9M
$-202.5M
Q4 24
$-14.1M
$-178.9M
Q3 24
$-82.2M
$-95.8M
Q2 24
$3.1M
$-97.5M
Q1 24
$793.0K
$-91.4M
Gross Margin
FFWM
FFWM
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FFWM
FFWM
RXRX
RXRX
Q4 25
-97.5%
-304.8%
Q3 25
-92.7%
-3327.6%
Q2 25
-21.1%
-916.8%
Q1 25
8.8%
-1297.9%
Q4 24
-247.7%
-4042.4%
Q3 24
-1276.7%
-377.1%
Q2 24
4.6%
-697.4%
Q1 24
-0.2%
-698.4%
Net Margin
FFWM
FFWM
RXRX
RXRX
Q4 25
-97.9%
-304.2%
Q3 25
-230.1%
-3135.3%
Q2 25
-15.0%
-894.2%
Q1 25
9.7%
-1373.3%
Q4 24
-152.2%
-3935.5%
Q3 24
-896.9%
-367.5%
Q2 24
5.4%
-676.6%
Q1 24
1.6%
-662.4%
EPS (diluted)
FFWM
FFWM
RXRX
RXRX
Q4 25
$-0.09
$-0.17
Q3 25
$-1.78
$-0.36
Q2 25
$-0.09
$-0.41
Q1 25
$0.08
$-0.50
Q4 24
$-0.24
$-0.56
Q3 24
$-1.23
$-0.34
Q2 24
$0.05
$-0.40
Q1 24
$0.01
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FFWM
FFWM
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$1.6B
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$912.6M
$1.1B
Total Assets
$11.9B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FFWM
FFWM
RXRX
RXRX
Q4 25
$1.6B
$743.3M
Q3 25
$1.7B
$659.8M
Q2 25
$1.1B
$525.1M
Q1 25
$1.0B
$500.5M
Q4 24
$1.0B
$594.4M
Q3 24
$1.1B
$427.6M
Q2 24
$1.4B
$474.3M
Q1 24
$1.6B
$296.3M
Total Debt
FFWM
FFWM
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FFWM
FFWM
RXRX
RXRX
Q4 25
$912.6M
$1.1B
Q3 25
$917.9M
$1.0B
Q2 25
$1.1B
$919.1M
Q1 25
$1.1B
$933.9M
Q4 24
$1.1B
$1.0B
Q3 24
$1.1B
$524.6M
Q2 24
$933.2M
$584.4M
Q1 24
$928.7M
$401.2M
Total Assets
FFWM
FFWM
RXRX
RXRX
Q4 25
$11.9B
$1.5B
Q3 25
$11.9B
$1.4B
Q2 25
$11.6B
$1.3B
Q1 25
$12.6B
$1.3B
Q4 24
$12.6B
$1.4B
Q3 24
$13.4B
$726.5M
Q2 24
$13.7B
$775.9M
Q1 24
$13.6B
$557.8M
Debt / Equity
FFWM
FFWM
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FFWM
FFWM
RXRX
RXRX
Operating Cash FlowLast quarter
$-31.9M
$-46.1M
Free Cash FlowOCF − Capex
$-35.2M
$-47.3M
FCF MarginFCF / Revenue
-72.8%
-133.1%
Capex IntensityCapex / Revenue
6.9%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.9M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FFWM
FFWM
RXRX
RXRX
Q4 25
$-31.9M
$-46.1M
Q3 25
$9.2M
$-117.4M
Q2 25
$-16.3M
$-76.4M
Q1 25
$-552.0K
$-132.0M
Q4 24
$-8.7M
$-115.4M
Q3 24
$14.2M
$-59.2M
Q2 24
$-9.1M
$-82.2M
Q1 24
$7.2M
$-102.3M
Free Cash Flow
FFWM
FFWM
RXRX
RXRX
Q4 25
$-35.2M
$-47.3M
Q3 25
$8.6M
$-117.6M
Q2 25
$-16.7M
$-79.6M
Q1 25
$-2.5M
$-133.8M
Q4 24
$-11.4M
$-116.7M
Q3 24
$13.4M
$-63.8M
Q2 24
$-9.4M
$-83.4M
Q1 24
$5.9M
$-109.0M
FCF Margin
FFWM
FFWM
RXRX
RXRX
Q4 25
-72.8%
-133.1%
Q3 25
13.5%
-2272.5%
Q2 25
-32.4%
-413.9%
Q1 25
-3.5%
-907.4%
Q4 24
-123.5%
-2567.7%
Q3 24
146.2%
-244.6%
Q2 24
-16.3%
-578.5%
Q1 24
11.6%
-789.9%
Capex Intensity
FFWM
FFWM
RXRX
RXRX
Q4 25
6.9%
3.5%
Q3 25
1.0%
4.7%
Q2 25
0.8%
16.4%
Q1 25
2.8%
12.4%
Q4 24
29.4%
28.6%
Q3 24
9.0%
17.5%
Q2 24
0.4%
8.2%
Q1 24
2.5%
48.2%
Cash Conversion
FFWM
FFWM
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
-0.08×
Q4 24
Q3 24
Q2 24
-2.96×
Q1 24
9.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons